Understanding Alyglo™
Alyglo™ (immune globulin intravenous, human‑stwk) is approved by the U.S. FDA for the treatment of primary humoral immunodeficiency (PI) in adults aged 17 and older. It replaces missing IgG antibodies to help reduce infections in patients with immune system deficiencies such as congenital agammaglobulinemia, CVID, and Wiskott‑Aldrich syndrome.
How Alyglo™ Works:
- Provides passive immunity by supplying functional IgG antibodies to support immune defense.
- Helps prevent serious bacterial infections in patients with impaired antibody production.
- Offers flexible dosing every 3–4 weeks via intravenous infusion, with adjustable infusion rates based on patient tolerance.
FDA Approval:
2023 – Alyglo™ gained FDA approval for use in adults with primary humoral immunodeficiency
For more information, please visit the Alyglo™ patient website. Speak with your healthcare provider to determine if Alyglo™ is the right treatment option for you.
